Miles Wang, an OpenAI researcher whose work consists of utilizing AI to speed up scientific and organic discovery, is leaving the ChatGPT maker to launch a brand new startup targeted on growing AI fashions for drug discovery, in keeping with 4 individuals with information of his plans. A number of different OpenAI researchers are anticipated to affix the brand new firm.
Wang is in talks to lift about $200 million at a $2 billion valuation, two of the individuals mentioned. Lightspeed is in discussions to steer the funding spherical, in keeping with sources. Talks are ongoing, the deal might not be remaining and particulars might change.
Wang disputed the story’s funding figures and outline of the corporate however didn’t specify the right numbers or particulars. Lightspeed didn’t reply to a request for remark.
The funding discussions level to investor curiosity in making use of AI to make breakthroughs in life sciences. Chai Discovery, a two-year-old startup growing AI fashions that may predict molecular interactions to establish new medication, introduced on Tuesday that it raised $400 million at a $3.8 billion valuation. (Co-founder Josh Meier additionally handed by way of OpenAI as a researcher.) In the meantime, Google DeepMind spinout Isomorphic Labs, which additionally develops AI fashions for drug discovery, raised a $2.1 billion Collection B in Could.
Wang’s new startup could also be engaged on AI fashions that may assist discover new makes use of for current medication and probably those who beforehand failed in trials, a few sources advised TechCrunch. Discovering new makes use of for FDA-approved medication may end up in considerably quicker time to income than growing new medication from scratch, as these medicines have already been examined for security.
Wang joined OpenAI in 2024 after dropping out from Harvard, the place he was engaged on a bachelor’s diploma in pc science. (In recent times, buyers are as soon as once more comfy betting on younger founders who haven’t completed college.)
At OpenAI, he co-authored analysis papers, together with evaluating how AI fashions can automate and accelerate scientific discovery.
If you buy by way of hyperlinks in our articles, we may earn a small commission. This doesn’t have an effect on our editorial independence.
